In this retrospective analysis, we assessed the short-term risk of treatmentassessed the short-term risk of treatmentemergent diabetes (TED) among patients emergent diabetes (TED) among patients with schizophrenia during clinical trials of with schizophrenia during clinical trials of antipsychotic medications. antipsychotic medications.
Method
Method From a non-diabetic cohort of From a non-diabetic cohort of patients with schizophrenia ( patients with schizophrenia (n n¼5013), the 5013), the relationship between baseline non-fasting relationship between baseline non-fasting glucose measurement, presence at glucose measurement, presence at baseline of risk factors for diabetes, weight baseline of risk factors for diabetes, weight gain and therapy assignment on the risk of gain and therapy assignment on the risk of treatment-emergent diabetes were treatment-emergent diabetes were assessed. assessed.
Results
Results Atthe baseline assessment, Atthe baseline assessment, about a third of patients identified with about a third of patients identified with TED during treatment had non-fasting TED during treatment had non-fasting glucose levels over 7.8 mmol/l and twoglucose levels over 7.8 mmol/l and twothirds had multiple diabetes risk factors. thirds had multiple diabetes risk factors. Both baseline non-fasting glucoselevel and Both baseline non-fasting glucoselevel and the presence of multiple pre-existing the presence of multiple pre-existing diabetes risk factors appeared to have a diabetes risk factors appeared to have a major impact on the risk of developing major impact on the risk of developing diabetes. diabetes.
Conclusions Conclusions Overall, risk factors for
Overall, risk factors for diabetes in patients with schizophrenia diabetes in patients with schizophrenia overlap those in the general population. overlap those in the general population. The results also suggestthat many patients The results also suggestthat many patients identified withTED might have had preidentified withTED might have had preexisting glycaemic abnormalities or a high existing glycaemic abnormalities or a high baseline burden of diabetes risk factors. baseline burden of diabetes risk factors.
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A number of reports have described new-A number of reports have described newonset diabetes in temporal association with onset diabetes in temporal association with atypical antipsychotic treatment (Koller atypical antipsychotic treatment (Koller et al et al, 2001 (Koller et al et al, , 2003 Koller & Doraiswamy, , 2001 , 2003 Koller & Doraiswamy, 2002) . In many of the reported cases, dia-2002) . In many of the reported cases, diabetes was noted in relatively young patients betes was noted in relatively young patients (mean age about 40 years) and was (mean age about 40 years) and was diagnosed within 3-6 months of first presdiagnosed within 3-6 months of first prescription of the atypical antipsychotic cription of the atypical antipsychotic medication. Evaluation of the relatedness medication. Evaluation of the relatedness of diabetes to atypical antipsychotic use of diabetes to atypical antipsychotic use from case reports is complicated by a numfrom case reports is complicated by a number of factors, including the increasing ber of factors, including the increasing prevalence of diabetes in the general popuprevalence of diabetes in the general population and data indicating that a substantial lation and data indicating that a substantial number of individuals with diabetes are number of individuals with diabetes are undiagnosed. undiagnosed.
Data from the National Health and Data from the National Health and Nutrition Examination Survey (NHANES) Nutrition Examination Survey (NHANES) III (1988 III ( -1994 indicate that diagnosed III (1988 III ( -1994 indicate that diagnosed diabetes was present in 5.1% of the US diabetes was present in 5.1% of the US adult population (Harris adult population (Harris et al et al, 1998) . , 1998). Subsequent reports from the Center for Subsequent reports from the Center for Disease Control have described a continued Disease Control have described a continued increase (about 30%) in the prevalence of increase (about 30%) in the prevalence of diabetes during the 1990s, with the largest diabetes during the 1990s, with the largest increase (70%) in individuals in the 30-39 increase (70%) in individuals in the 30-39 year age range (Mokdad year age range (Mokdad et al et al, 2000) . , 2000). Further data from NHANES III suggested Further data from NHANES III suggested that diabetes was undiagnosed in as many that diabetes was undiagnosed in as many as a third of patients (Harris as a third of patients (Harris et al et al, 1998) . , 1998). Results from another large survey support Results from another large survey support this finding that approximately half of this finding that approximately half of patients in Australia with diabetes were patients in Australia with diabetes were undiagnosed (Dunstan undiagnosed (Dunstan et al et al, 2002) . , 2002). The prevalence of diagnosed diabetes in The prevalence of diagnosed diabetes in patients with schizophrenia appears to patients with schizophrenia appears to exceed that of the general population by exceed that of the general population by 2-fold (Dixon 2-fold (Dixon et al et al, 2000) . Patients with , 2000) . Patients with schizophrenia generally have poorer physischizophrenia generally have poorer physical health (Brown cal health (Brown et al et al, 1999; Osborn , 1999; Osborn 2001) , and less than adequate overall 2001), and less than adequate overall health care (Phelan health care (Phelan et al et al, 2001; Wang , 2001; Wang et et al al, 2002 , 2002a a) compared with the general popu-) compared with the general population. The symptoms of the psychosis itself lation. The symptoms of the psychosis itself may hinder the ability or willingness of the may hinder the ability or willingness of the patient to communicate potential physical patient to communicate potential physical probems (Felker probems (Felker et al et al, 1996; Jeste , 1996; Jeste et al et al, , 1996) . Thus, it is likely that the prevalence 1996). Thus, it is likely that the prevalence of unrecognised diabetes in patients with of unrecognised diabetes in patients with schizophrenia is at least as high as that in schizophrenia is at least as high as that in the general population. the general population.
Reasons for an increased prevalence of Reasons for an increased prevalence of diabetes among patients with schizodiabetes among patients with schizophrenia remain speculative. However, phrenia remain speculative. However, Dixon Dixon et al et al (2000) reported that in a sur- (2000) reported that in a survey of several large databases containing vey of several large databases containing medical information on patients with medical information on patients with schizophrenia, the patients with diabetes schizophrenia, the patients with diabetes were more likely to be older, non-White, were more likely to be older, non-White, and to have hypertensionand to have hypertension -findings findings consistent with those in the general popuconsistent with those in the general population. In a more recent review of 45 publation. In a more recent review of 45 published case reports of new-onset diabetes lished case reports of new-onset diabetes in patients receiving atypical agents, Jin in patients receiving atypical agents, Jin et et al al (2002) noted that 84% of the patients (2002) noted that 84% of the patients were overweight at baseline assessment, were overweight at baseline assessment, 42% had a positive family history of 42% had a positive family history of diabetes and 49% had high-risk ethnic diabetes and 49% had high-risk ethnic backgrounds (African or Hispanic). The backgrounds (African or Hispanic). The assessment of case reports is complicated assessment of case reports is complicated by several factors, which include inconsisby several factors, which include inconsistent reporting of important demographic tent reporting of important demographic and other variables that might affect glyand other variables that might affect glycaemic control, reporting bias and lack of caemic control, reporting bias and lack of an adequate control group. In addition, an adequate control group. In addition, case reports cannot be used to determine case reports cannot be used to determine causal relationships between individual causal relationships between individual therapies and treatment-emergent diabetes. therapies and treatment-emergent diabetes.
Weight gain -a body mass index (BMI) Weight gain -a body mass index (BMI) of more than 25 kg/m of more than 25 kg/m 2 2 -is a risk factor for -is a risk factor for diabetes (Chan diabetes (Chan et al et al, 1994; Colditz , 1994; Colditz et al et al, , 1995) , and weight gain can occur during 1995), and weight gain can occur during treatment with most of the atypical antitreatment with most of the atypical antipsychotic medications (Allison psychotic medications (Allison et al et al, 1999) . , 1999). However, in some cases, new-onset diabetes However, in some cases, new-onset diabetes has been reported in patients without weight has been reported in patients without weight gain (Koller gain (Koller et al et al, 2001; Henderson, 2002; , 2001; Henderson, 2002; Koller & Doraiswamy, 2002) . Further, no Koller & Doraiswamy, 2002) . Further, no association between weight gain and newassociation between weight gain and newonset diabetes was noted in a naturalistic onset diabetes was noted in a naturalistic study of patients receiving clozapine study of patients receiving clozapine (Henderson (Henderson et al et al, 2000) . These observations , 2000). These observations have led to further speculation that some of have led to further speculation that some of the atypical antipsychotic medications may the atypical antipsychotic medications may increase risk for diabetes by a weightincrease risk for diabetes by a weightindependent mechanism. independent mechanism.
Given the growing interest in a possible Given the growing interest in a possible association between diabetes and antiassociation between diabetes and antipsychotic medications, a systematic repsychotic medications, a systematic reevaluation of risk factor profiles of patients evaluation of risk factor profiles of patients with treatment-emergent diabetes (TED) is with treatment-emergent diabetes (TED) is warranted. In this retrospective analysis of warranted. In this retrospective analysis of a large clinical trials database, our objecta large clinical trials database, our objectives were: (a) to identify patients with ives were: (a) to identify patients with schizophrenia who exhibited TED; (b) to schizophrenia who exhibited TED; (b) to compare the entry characteristics, including compare the entry characteristics, including pre-randomisation risk factor profiles, of pre-randomisation risk factor profiles, of TED patients with those who maintained TED patients with those who maintained normal glucose tolerance during treatment; normal glucose tolerance during treatment; and (c) to examine the influence of and (c) to examine the influence of treatment-emergent weight gain or therapy treatment-emergent weight gain or therapy assignment on the development of TED. assignment on the development of TED.
METHOD METHOD
Patient population and study Patient population and study designs designs
Twenty-four studies were identified Twenty-four studies were identified from the olanzapine clinical trial from the olanzapine clinical trial database in which patient weight and database in which patient weight and post-randomisation plasma glucose meapost-randomisation plasma glucose measurements were available at multiple time surements were available at multiple time points. For many of the studies, the details points. For many of the studies, the details of the study designs, patient characteristics of the study designs, patient characteristics (age, gender, race, illness characteristics), (age, gender, race, illness characteristics), and efficacy and safety results have been and efficacy and safety results have been previously published (Beasley previously published (Beasley et al et al, , 1996 (Beasley et al et al, , 1996a Tollefson ; Tollefson et al et al, 1997 Tollefson et al et al, , 1999 Tollefson et al et al, , , 1997 Tollefson et al et al, , 1999 Tollefson et al et al, , 2001 Tran 2001; Tran et al et al, 1997) . Briefly, study par-, 1997). Briefly, study participants were in-patients or out-patients, ticipants were in-patients or out-patients, aged 18-65 years, diagnosed with DSMaged 18-65 years, diagnosed with DSM-III-R or DSM-IV schizophrenia or related III-R or DSM-IV schizophrenia or related disorders (American Psychiatric Associadisorders (American Psychiatric Association, 1987 Association, , 1994 , and had provided tion, 1987, 1994) , and had provided written informed consent after the study dewritten informed consent after the study design and possible adverse events were design and possible adverse events were described. Participation criteria were similar scribed. Participation criteria were similar among the pooled trials, except that among the pooled trials, except that studies examining clozapine were limited studies examining clozapine were limited to patients with treatment-refractory to patients with treatment-refractory disease (Tollefson disease (Tollefson et al et al, 1999 (Tollefson et al et al, , 2001 (Tollefson et al et al, ) and, , 1999 (Tollefson et al et al, , 2001 and, in several studies comparing olanzapine in several studies comparing olanzapine with risperidone, entry criteria excluded with risperidone, entry criteria excluded patients with cardiovascular disease from patients with cardiovascular disease from participation in the original trial (Tran participation in the original trial (Tran et al et al, 1997) . All studies included a medi-, 1997). All studies included a medication wash-out period of 2-9 days and cation wash-out period of 2-9 days and a double-masked treatment period of a double-masked treatment period of 6-52 weeks, followed by an olanzapine 6-52 weeks, followed by an olanzapine open-label extension phase in some cases. open-label extension phase in some cases. For studies with medication crossover, For studies with medication crossover, only the initial monotherapy treatment only the initial monotherapy treatment period was included in the analyses. period was included in the analyses. During During the double-masked treatment the double-masked treatment period, all patients received therapeutic period, all patients received therapeutic doses of a single antipsychotic medication doses of a single antipsychotic medication (olanzapine 5-25 mg/day, haloperidol (olanzapine 5-25 mg/day, haloperidol 5-20 mg/day, risperidone 4-12 mg/day, 5-20 mg/day, risperidone 4-12 mg/day, clozapine 200-600 mg/day) or placebo. clozapine 200-600 mg/day) or placebo.
Non-fasting glucose measurements Non-fasting glucose measurements
Non-fasting glucose levels were analysed Non-fasting glucose levels were analysed by Covance Inc. using a photometric chemby Covance Inc. using a photometric chemistry analyser (Hitachi 747-200; Roche istry analyser (Hitachi 747-200; Roche Diagnostics, Indianapolis, Indiana, USA). Diagnostics, Indianapolis, Indiana, USA). The frequency of sample collection was The frequency of sample collection was specified by each study protocol. In specified by each study protocol. In general, two samples were obtained pregeneral, two samples were obtained prerandomisation and after that, samples were randomisation and after that, samples were usually obtained weekly for the first usually obtained weekly for the first 6 weeks and monthly or bi-weekly there-6 weeks and monthly or bi-weekly thereafter. In case of multiple glucose measureafter. In case of multiple glucose measurements for the same visit, only the ments for the same visit, only the maximum observation was considered. maximum observation was considered. The analyses included all measurements The analyses included all measurements up to and including the day after the last up to and including the day after the last day of treatment. day of treatment. 
Classification of patients Classification of patients

Statistical methods Statistical methods
Data from 24 studies from the olanzapine Data from 24 studies from the olanzapine clinical trial database were pooled for these clinical trial database were pooled for these analyses. To account for variation in observation To account for variation in observation times for individual therapy groups, a timetimes for individual therapy groups, a timeto-event analysis using the Cox proportto-event analysis using the Cox proportional hazards model was employed to ional hazards model was employed to assess the risk of TED. Specifically, the assess the risk of TED. Specifically, the Cox model assessed the impact of mean Cox model assessed the impact of mean non-fasting glucose values or the presence non-fasting glucose values or the presence of pre-existing risk factors for diabetes on of pre-existing risk factors for diabetes on the subsequent risk of being identified with the subsequent risk of being identified with TED. The Cox proportional hazards model TED. The Cox proportional hazards model was also used to assess the impact of weight was also used to assess the impact of weight gain and therapy assignment on the risk of gain and therapy assignment on the risk of being identified with TED being identified with TED v v. 'not TED' . 'not TED' (UGT plus NGT cohorts). Because of the (UGT plus NGT cohorts). Because of the small number of events in individual thersmall number of events in individual therapy groups, treatment group results were apy groups, treatment group results were compared between olanzapine and noncompared between olanzapine and nonolanzapine groups (including haloperidol, olanzapine groups (including haloperidol, risperidone and placebo). Unless otherwise risperidone and placebo). Unless otherwise specified, the Cox proportional hazards specified, the Cox proportional hazards model included a single test covariate (basemodel included a single test covariate (baseline mean non-fasting glucose concentraline mean non-fasting glucose concentration, baseline risk factors for diabetes, tion, baseline risk factors for diabetes, treatment-emergent weight gain, or therapy treatment-emergent weight gain, or therapy assignment) along with study protocol. The assignment) along with study protocol. The study protocol was also included as a strastudy protocol was also included as a stratification variable in the model to control tification variable in the model to control for effects of pooling data from several for effects of pooling data from several clinical trials. clinical trials.
RESULTS RESULTS
Categorisation of patients Categorisation of patients
Of the 5529 patients enrolled, 149 patients Of the 5529 patients enrolled, 149 patients were identified with pre-existing diabetes were identified with pre-existing diabetes and were excluded from the TED analysis. and were excluded from the TED analysis. Post-randomisation glucose values were Post-randomisation glucose values were available for 5013 patients not known to available for 5013 patients not known to be diabetic by diagnosis, use of antidiabetic be diabetic by diagnosis, use of antidiabetic medication, or pre-randomisation glucose medication, or pre-randomisation glucose values. The majority (60%) of these values. The majority (60%) of these patients received olanzapine, followed by patients received olanzapine, followed by haloperidol (24%), risperidone (8%), haloperidol (24%), risperidone (8%), placebo (4%) and clozapine (4%) placebo (4%) and clozapine (4%) ( Table 1 ). After randomisation, most (Table 1 ). After randomisation, most patients ( patients (n n¼4637, 92.5%) appeared to 4637, 92.5%) appeared to maintain normoglycaemia and were considmaintain normoglycaemia and were considered to have NGT. Of the remaining ered to have NGT. Of the remaining patients, 94 (1.9%) were identified with patients, 94 (1.9%) were identified with TED and 282 (5.7%) exhibited an inter-TED and 282 (5.7%) exhibited an intermediate level of hyperglycaemia and, in mediate level of hyperglycaemia and, in the absence of more definitive testing, were the absence of more definitive testing, were considered considered to have UGT ( Table 1 ). The to have UGT ( Table 1 ). The mean postmean post-randomisation observation time randomisation observation time varied among the individual therapy assignvaried among the individual therapy assignments with a mean of 205 (s.d. 283) days ments with a mean of 205 (s.d. 283) days (median 86 days), and a maximum obser-(median 86 days), and a maximum observation time of 1775 days ( Table 1 ). The vation time of 1775 days ( Table 1 ). The mean weight gain for each therapy at endmean weight gain for each therapy at endpoint (LOCF) is also presented in Table 1 . point (LOCF) is also presented in Table 1 .
Risk factors for treatmentRisk factors for treatmentemergent diabetes emergent diabetes
Risk factors at study entry Risk factors at study entry At study entry, mean non-fasting glucose At study entry, mean non-fasting glucose levels for TED patients were significantly levels for TED patients were significantly higher than for NGT patients ( Table 2 ). higher than for NGT patients ( 511.1 mmol/l 11.1 mmol/l at entry ( at entry (n n¼27) who were not excluded 27) who were not excluded from the analysis, 9 were categorised in from the analysis, 9 were categorised in the TED group, 5 were categorised in the the TED group, 5 were categorised in the UGT group, and 13 were categorised in UGT group, and 13 were categorised in the NGT group. the NGT group.
Patients subsequently identified as Patients subsequently identified as having TED were significantly older, more having TED were significantly older, more obese and more likely to be hypertensive, obese and more likely to be hypertensive, non-White, female, or have baseline dysnon-White, female, or have baseline dysglycaemia than NGT patients ( Table 2) . glycaemia than NGT patients ( Table 2) . Sixty-four per cent of TED patients Sixty-four per cent of TED patients possessed multiple risk factors for diabetes possessed multiple risk factors for diabetes compared with 21% of NGT patients compared with 21% of NGT patients (Fig. 2) . Baseline characteristics of patients ( Fig. 2) . Baseline characteristics of patients subsequently identified with TED demonsubsequently identified with TED demonstrated that substantial numbers had basestrated that substantial numbers had baseline non-fasting glucose levels line non-fasting glucose levels 5 57.8 mmol/ 7.8 mmol/ l or multiple pre-existing risk factors for l or multiple pre-existing risk factors for diabetes in each of the individual treatment diabetes in each of the individual treatment groups (Table 2 ). Approximately half of the groups (Table 2 ). Approximately half of the cases of TED were identified within 3 cases of TED were identified within 3 months of trial entry. For these 'early' months of trial entry. For these 'early' TED patients, the entry glucose was TED patients, the entry glucose was 7.9 (s.d. 2.2) mmol/l and 71% possessed at 7.9 (s.d. 2.2) mmol/l and 71% possessed at least two risk factors for diabetes at entry. least two risk factors for diabetes at entry.
As expected, entry non-fasting glucose As expected, entry non-fasting glucose had a highly significant impact on the risk had a highly significant impact on the risk of TED. The risk of being identified with of TED. The risk of being identified with TED was substantially greater for patients TED was substantially greater for patients s 9 6 s 9 6 with entry non-fasting glucose with entry non-fasting glucose 5 57.8 mmol/ 7.8 mmol/ l: hazard ratio (HR) 31.9; 95% CI 19.6-l: hazard ratio (HR) 31.9; 95% CI 19.6-52.0; 52.0; P P5 50.001. Even at lower entry 0.001. Even at lower entry glucose levels, the risk of TED was still glucose levels, the risk of TED was still markedly elevated. For example, in patients markedly elevated. For example, in patients with non-fasting glucose of with non-fasting glucose of 5 56.7 mmol/l, 6.7 mmol/l, the risk of TED was elevated (HR 11.85, the risk of TED was elevated (HR 11.85, ; P P5 50.001) (Fig. 3) . 0.001) (Fig. 3) . Further, the risk for TED was 9 times Further, the risk for TED was 9 times greater for patients with baseline random greater for patients with baseline random plasma glucose plasma glucose 5 56.7 mmol/l (HR 9.6, 6.7 mmol/l (HR 9.6, 95% CI 6.2-14.8; 95% CI 6.2-14.8; P P5 50.001). 0.001). The presence of multiple baseline risk The presence of multiple baseline risk factors for diabetes (age, BMI, nonfactors for diabetes (age, BMI, nonWhite ethnicity, hypertension and dysWhite ethnicity, hypertension and dysglycaemia) also had a highly significant glycaemia) also had a highly significant impact on the risk of being identified with impact on the risk of being identified with TED. Without adjusting for entry non-TED. Without adjusting for entry nonfasting glucose in the Cox proportional fasting glucose in the Cox proportional hazards model, patients with two or more hazards model, patients with two or more risk factors at entry were nearly 6 times risk factors at entry were nearly 6 times more likely to be identified with TED more likely to be identified with TED (HR 5.70, 95% CI 3.6-9.0; (HR 5.70, 95% CI 3.6-9.0; P P5 50.001) than 0.001) than patients with one or no risk factor. patients with one or no risk factor.
An interaction between entry nonAn interaction between entry nonfasting glucose value and number of prefasting glucose value and number of preexisting diabetes risk factors would be existing diabetes risk factors would be expected. Among patients with entry expected. Among patients with entry glucose values glucose values 5 57.8 mmol/l and two or 7.8 mmol/l and two or more baseline risk factors for diabetes, more baseline risk factors for diabetes, 40% (26 of 64 patients) were identified 40% (26 of 64 patients) were identified with TED. In contrast, less than 1% (26 with TED. In contrast, less than 1% (26 of 3795) of patients with of 3795) of patients with 4 41 risk factor 1 risk factor and an entry glucose and an entry glucose 5 57.8 mmol/l were 7.8 mmol/l were identified with TED. Furthermore, for paidentified with TED. Furthermore, for patients with entry glucose tients with entry glucose 5 57.8 mmol/l, the 7.8 mmol/l, the likelihood of being identified with TED likelihood of being identified with TED was greater if multiple (two or more) basewas greater if multiple (two or more) baseline risk factors were present: 3.2% (34 out line risk factors were present: 3.2% (34 out of 1068) of patients with normal glucose of 1068) of patients with normal glucose and multiple risk factors were identified and multiple risk factors were identified with TED. with TED.
Of the 94 TED patients, nine appeared Of the 94 TED patients, nine appeared to lack risk factors for diabetes at study to lack risk factors for diabetes at study entry. However, within this subgroup, entry. However, within this subgroup, detailed review revealed that seven patients detailed review revealed that seven patients were overweight (BMI 26.5 to 26.9 kg/m were overweight (BMI 26.5 to 26.9 kg/m 2 2 or weight or weight 4 4118 kg), over 35 years of age, 118 kg), over 35 years of age, or had questionable entry non-fasting or had questionable entry non-fasting glucose levels (range 7.8-10 mmol/l). glucose levels (range 7.8-10 mmol/l). The The two remaining patients experienced subtwo remaining patients experienced substantial weight gain ( stantial weight gain (4 413 kg) prior to 13 kg) prior to identification of TED. identification of TED.
A subset of patients ( A subset of patients (n n¼282) with re-282) with repeated post-randomisation glucose levels peated post-randomisation glucose levels 5 57.8 mmol/l, but an insufficient hyper-7.8 mmol/l, but an insufficient hyperglycaemia to meet criteria for TED were glycaemia to meet criteria for TED were identified. This appeared to be a heteroidentified. This appeared to be a heterogeneous group in terms of glycaemic geneous group in terms of glycaemic control and because confirmatory testing control and because confirmatory testing data (e.g. fasting plasma glucose or OGTT) data (e.g. fasting plasma glucose or OGTT) were not available to define glycaemic were not available to define glycaemic status more precisely, these patients were status more precisely, these patients were considered to have UGT and were analysed considered to have UGT and were analysed separately. Overall, this group possessed separately. Overall, this group possessed entry characteristics (Table 2 ) and risk entry characteristics (Table 2 ) and risk factor profiles (Fig. 2) intermediate to those factor profiles (Fig. 2) intermediate to those of the TED and NGT groups. At study of the TED and NGT groups. At study entry, the mean non-fasting glucose for entry, the mean non-fasting glucose for patients identified as possessing UGT was patients identified as possessing UGT was significantly higher than NGT patients significantly higher than NGT patients and 37% of the UGT patients had entry and 37% of the UGT patients had entry glucose values glucose values 5 56.1 mmol/l, with 6.1 mmol/l, with 7% 7%5 57.8 mmol/l ( Table 2 and Fig. 1 ). The 7.8 mmol/l ( Table 2 and Fig. 1 ). The number and percentage of patients identinumber and percentage of patients identified with UGT in individual therapy groups fied with UGT in individual therapy groups with baseline mean non-fasting glucose with baseline mean non-fasting glucose 5 57.8 mmol/l or with 2 or more baseline 7.8 mmol/l or with 2 or more baseline risk factors for diabetes are presented in risk factors for diabetes are presented in Table 3 . Table 3 .
Post-randomisation risk factors Post-randomisation risk factors
Patients identified as having TED gained Patients identified as having TED gained slightly more weight than NGT patients slightly more weight than NGT patients (3.9 kg (3.9 kg v v. 2.7 kg, baseline to end-point, . 2.7 kg, baseline to end-point, LOCF). However, observation times were LOCF). However, observation times were longer for TED patients compared with longer for TED patients compared with the overall NGT group (data not shown). the overall NGT group (data not shown). To adjust for differences in observation To adjust for differences in observation time, a time-to-event analysis was pertime, a time-to-event analysis was performed using a Cox proportional hazards formed using a Cox proportional hazards s 9 7 s 9 7 Distribution of baseline mean non-fasting glucose levels by post-randomisation glycaemic category:
normal glucose tolerance (NGT), treatment-emergent diabetes (TED) and uncertain glucose, tolerance (UGT). normal glucose tolerance (NGT), treatment-emergent diabetes (TED) and uncertain glucose, tolerance (UGT).
Asterisk denotes 2 patients with a single glucose measurement at entry. Asterisk denotes 2 patients with a single glucose measurement at entry. model. In this analysis, the impact of model. In this analysis, the impact of weight gain (7% or more of the patient's weight gain (7% or more of the patient's initial body weight) as a categorical coinitial body weight) as a categorical covariate on the risk of being identified with variate on the risk of being identified with TED did not achieve statistical significance TED did not achieve statistical significance (HR 1.21, 95% CI 0.77-1.90, (HR 1.21, 95% CI 0.77-1.90, P P¼0.414; 0.414; Fig. 3 ), without adjusting for baseline glu- Fig. 3 ), without adjusting for baseline glucose concentration or number of pre-existing cose concentration or number of pre-existing risk factors. risk factors.
The risk of TED for patients receiving The risk of TED for patients receiving olanzapine olanzapine v v. non-olanzapine interventions . non-olanzapine interventions (risperidone, haloperidol and placebo) was (risperidone, haloperidol and placebo) was also assessed using the Cox proportional also assessed using the Cox proportional hazards model. As there were relatively hazards model. As there were relatively few TED events in individual nonfew TED events in individual nonolanzapine treatment groups, the risk of olanzapine treatment groups, the risk of TED was evaluated between patients re-TED was evaluated between patients receiving olanzapine and a pooled cohort of ceiving olanzapine and a pooled cohort of patients receiving the other non-olanzapine patients receiving the other non-olanzapine interventions (Table 1) . Because clozapine, interventions (Table 1) . Because clozapine, like olanzapine, has been suggested to be like olanzapine, has been suggested to be more closely associated with treatmentmore closely associated with treatmentemergent diabetes than other antipsychotic emergent diabetes than other antipsychotic medications, clozapine was omitted from medications, clozapine was omitted from the non-olanzapine group to avoid the pothe non-olanzapine group to avoid the potential for increasing the risk of diabetes tential for increasing the risk of diabetes in the non-olanzapine group. Using the in the non-olanzapine group. Using the Cox proportional hazards model, without Cox proportional hazards model, without adjusting for baseline random plasma gluadjusting for baseline random plasma glucose level, baseline number of risk factors cose level, baseline number of risk factors or weight gain, the short-term risk for or weight gain, the short-term risk for TED patients treated with olanzapine was TED patients treated with olanzapine was not significantly greater than in a pooled not significantly greater than in a pooled cohort of patients receiving risperidone, cohort of patients receiving risperidone, haloperidol and placebo (HR 1.46, 95% haloperidol and placebo (HR 1.46, 95% CI 0.83-2.57, CI 0.83-2.57, P P¼0.186; Fig. 3) . In a sepa-0.186; Fig. 3) . In a separate analysis that included baseline glucose rate analysis that included baseline glucose concentration, number of baseline risk facconcentration, number of baseline risk factors and weight gain as continuous covaritors and weight gain as continuous covariates, the risk for TED was also not ates, the risk for TED was also not significantly different between the olanzasignificantly different between the olanzapine and non-olanzapine treatment groups pine and non-olanzapine treatment groups ( (P P¼0.220). In this multivariate analysis, 0.220). In this multivariate analysis, both baseline glucose values and number both baseline glucose values and number of pre-existing risk factors remained highly of pre-existing risk factors remained highly significant ( significant (P P5 50.001) covariates, whereas 0.001) covariates, whereas treatment-emergent weight gain was not treatment-emergent weight gain was not significant ( significant (P P¼0.311). 0.311).
DISCUSSION DISCUSSION
In this retrospective analysis of a large clinIn this retrospective analysis of a large clinical trial database of patients with schizoical trial database of patients with schizophrenia, 94 cases of treatment-emergent phrenia, 94 cases of treatment-emergent diabetes (about 2% of the patient popudiabetes (about 2% of the patient population) were identified. The annualised lation) were identified. The annualised rates of TED were about 3% for patients rates of TED were about 3% for patients treated with olanzapine, haloperidol and treated with olanzapine, haloperidol and risperidone. The patients in the placebo risperidone. The patients in the placebo group had an annualised TED rate of about group had an annualised TED rate of about 5%, which was not statistically different 5%, which was not statistically different from the rate in the olanzapine treatment from the rate in the olanzapine treatment group. Only the patients treated with clozagroup. Only the patients treated with clozapine had a significantly greater rate (about pine had a significantly greater rate (about 11% per year; 11% per year; P P¼0.022 0.022 v v. olanzapine). . olanzapine). Assuming that the definition of TED used Assuming that the definition of TED used in this study truly reflects more conventin this study truly reflects more conventional definitions of diabetes, the rates of ional definitions of diabetes, the rates of new diabetes seen were significantly greater new diabetes seen were significantly greater than the rate that would be expected in the than the rate that would be expected in the general population (about 0.3% per year in general population (about 0.3% per year in US adults, with a peak incidence of about US adults, with a peak incidence of about 1% per year in the elderly; Harris 1% per year in the elderly; Harris et al et al, , 1998). Although it is possible that the defi-1998). Although it is possible that the definition of TED used for these analyses might nition of TED used for these analyses might have led us to underestimate the actual incihave led us to underestimate the actual incidence of diabetes (see the paragraph disdence of diabetes (see the paragraph discussing study limitations, below), the rates cussing study limitations, below), the rates seen in our study are consistent with those seen in our study are consistent with those reported in other studies of patients with reported in other studies of patients with schizophrenia. Annualised rates of diabetes schizophrenia. Annualised rates of diabetes of 1-7% have been reported in several epi- . The increased incidence of diabetes relative to the general incidence of diabetes relative to the general population seen in these studies is present population seen in these studies is present regardless of the type of antipsychotic drug regardless of the type of antipsychotic drug s 9 8 s 9 8 . non-olanzapine (haloperidol, risperidone and placebo). prescribed. In addition, the elevated rate of prescribed. In addition, the elevated rate of diabetes seen in the placebo group in our diabetes seen in the placebo group in our study is consistent with the significantly study is consistent with the significantly increased risk of diabetes in patients with increased risk of diabetes in patients with mental illness (Tabata mental illness (Tabata et al et al, 1987; , 1987; Mukherjee Mukherjee et al et al, 1996; Dixon , 1996; Dixon et al et al, 2000) . , 2000). At entry into the clinical trials, patients in At entry into the clinical trials, patients in this study subsequently identified with TED this study subsequently identified with TED possessed significantly higher non-fasting possessed significantly higher non-fasting glucose levels and were much more likely to glucose levels and were much more likely to have multiple risk factors for diabetes than have multiple risk factors for diabetes than patients who maintained NGT. In general, patients who maintained NGT. In general, TED patients were significantly older, more TED patients were significantly older, more obese and more likely to be non-White, obese and more likely to be non-White, hypertensive or have non-fasting glucose hypertensive or have non-fasting glucose levels suggestive of pre-existing dysglylevels suggestive of pre-existing dysglycaemia (e.g. single pre-randomisation caemia (e.g. single pre-randomisation glucose value greater than 11.1 mmol/l) at glucose value greater than 11.1 mmol/l) at study entry than patients who appeared to study entry than patients who appeared to maintain normal glucose levels (NGT maintain normal glucose levels (NGT patients). Overall, results of this analysis patients). Overall, results of this analysis suggest that the majority of patients who suggest that the majority of patients who were identified with TED were likely to were identified with TED were likely to have pre-existing, unrecognised glycaemic have pre-existing, unrecognised glycaemic abnormalities or to have had a greater burabnormalities or to have had a greater burden of pre-existing risk factors for diabetes den of pre-existing risk factors for diabetes than patients who appeared to maintain than patients who appeared to maintain normoglycaemia. normoglycaemia.
Weight gain has been established as a Weight gain has been established as a risk factor for diabetes (Chan risk factor for diabetes (Chan et al et al, 1994; , 1994; Colditz Colditz et al et al, 1995) , and weight gain , 1995), and weight gain has been observed during treatment with has been observed during treatment with many antipsychotics (Allison many antipsychotics (Allison et al et al, 1999) . , 1999). However, some reports have failed to However, some reports have failed to demonstrate a relationship between weight demonstrate a relationship between weight gain and new-onset diabetes temporally gain and new-onset diabetes temporally associated with atypical antipsychotic treatassociated with atypical antipsychotic treatment (Koller ment (Koller et al et al, 2001 (Koller et al et al, , 2003 Henderson, , 2001 Henderson, , , 2003 Henderson, 2002; Koller & Doraiswamy, 2002) . A 2002; Koller & Doraiswamy, 2002) . A direct effect of atypical antipsychotic direct effect of atypical antipsychotic medications to promote dysglycaemia has medications to promote dysglycaemia has been postulated (Koller been postulated (Koller et al et al, 2001 (Koller et al et al, , 2003 , 2001 , 2003 Henderson, 2002) ; however, in a prospecHenderson, 2002); however, in a prospective randomised study of healthy volunteers tive randomised study of healthy volunteers ( (n n¼48) treated for approximately 2.5 48) treated for approximately 2.5 weeks with olanzapine or risperidone, there weeks with olanzapine or risperidone, there was no significant change in insulin was no significant change in insulin secretion or insulin sensitivity in the active secretion or insulin sensitivity in the active therapy groups after adjusting for the therapy groups after adjusting for the impact of weight gain (Sowell impact of weight gain (Sowell et al et al, , 2002 ). In the current analysis, weight gain 2002). In the current analysis, weight gain during the trials did not have a statistically during the trials did not have a statistically significant effect on the risk of TED, significant effect on the risk of TED, although patients with TED gained slightly although patients with TED gained slightly more weight than those who maintained more weight than those who maintained NGT. Evaluation of the relationship be-NGT. Evaluation of the relationship between weight gain and risk of diabetes tween weight gain and risk of diabetes might be confounded if significant numbers might be confounded if significant numbers of individuals with unrecognised preof individuals with unrecognised preexisting diabetes were present or if the existing diabetes were present or if the population was already at high risk of population was already at high risk of diabetes (Wannamethee & Shaper, 1999) . diabetes (Wannamethee & Shaper, 1999) . Even among individuals without preEven among individuals without preexisting diabetes but who are at high risk existing diabetes but who are at high risk for the disorder, it may be difficult to meafor the disorder, it may be difficult to measure a significant impact of further weight sure a significant impact of further weight gain (Wannamethee & Shaper, 1999) . In gain (Wannamethee & Shaper, 1999) . In our analysis, a substantial number of TED our analysis, a substantial number of TED patients appeared to have a high likelihood patients appeared to have a high likelihood of underlying glycaemic abnormalities or of underlying glycaemic abnormalities or possess multiple risk factors for diabetes possess multiple risk factors for diabetes at baseline (for example, about a third of at baseline (for example, about a third of patients in the TED group had entry nonpatients in the TED group had entry nonfasting glucose values fasting glucose values 5 57.8 mmol/l and 7.8 mmol/l and about two-thirds had two or more baseline about two-thirds had two or more baseline risk factors). This, coupled with the relarisk factors). This, coupled with the relatively short duration of observation, might tively short duration of observation, might have contributed to the non-significant imhave contributed to the non-significant impact of weight gain in the Cox proportional pact of weight gain in the Cox proportional hazards analysis. hazards analysis.
There has been increasing interest in a There has been increasing interest in a possible differential risk for diabetes among possible differential risk for diabetes among patients taking different antipsychotic patients taking different antipsychotic medications. When considering case reports medications. When considering case reports involving patients treated with atypical involving patients treated with atypical antipsychotics, the largest number are for antipsychotics, the largest number are for patients using olanzapine and clozapine patients using olanzapine and clozapine (Henderson, 2002; Jin (Henderson, 2002; Jin et al et al, 2002 , 2001) . Consequently, the current analysis probably represents a minicurrent analysis probably represents a minimal estimate of the number of cases of mal estimate of the number of cases of TED. Inclusion of the UGT post-randomis-TED. Inclusion of the UGT post-randomisation category may ameliorate this limitaation category may ameliorate this limitation to some extent in terms of the tion to some extent in terms of the descriptive findings; however, without defidescriptive findings; however, without definitive diagnostic testing, limited conclunitive diagnostic testing, limited conclusions regarding the true frequency of sions regarding the true frequency of abnormal glycaemic events can be drawn abnormal glycaemic events can be drawn from this heterogeneous group. It must also from this heterogeneous group. It must also be acknowledged that reasonable alternabe acknowledged that reasonable alternative classification paradigms for identifying tive classification paradigms for identifying patients with TED or UGT could be patients with TED or UGT could be employed: for example, use of 6.7 mmol/l employed: for example, use of 6.7 mmol/l glucose as the lower limit for UGT (Rolka glucose as the lower limit for UGT (Rolka et al et al, 2001 ), or exclusion of 27 patients , 2001), or exclusion of 27 patients with a single glucose value with a single glucose value 4 411.1 mmol/l 11.1 mmol/l at study entry. In addition, alternative at study entry. In addition, alternative termi terminology could be applied to the nology could be applied to the postpost-randomisation glycaemic categories, randomisation glycaemic categories, as our TED criteria do not strictly meet as our TED criteria do not strictly meet ADA criteria for diabetes in absence of ADA criteria for diabetes in absence of reported symptoms (American Diabetes reported symptoms (American Diabetes Association, 2002) . The clinical trials Association, 2002). The clinical trials database also lacked information on prior database also lacked information on prior antipsychotic treatment history and a numantipsychotic treatment history and a number of important risk factors for diabetes ber of important risk factors for diabetes (family history, previous history of im-(family history, previous history of impaired glucose tolerance or lipid profile) paired glucose tolerance or lipid profile) as these data were not collected in a sysas these data were not collected in a systematic fashion. Therefore, the risk factor tematic fashion. Therefore, the risk factor assessment may well represent an underestiassessment may well represent an underestimate of the true pre-existing risk burden. mate of the true pre-existing risk burden. Furthermore, some of the between-group Furthermore, some of the between-group comparisons for patients receiving different comparisons for patients receiving different treatments were limited by differences in treatments were limited by differences in sample sizes and duration of observation. sample sizes and duration of observation. Finally, a major limitation is that the cliniFinally, a major limitation is that the clinical trials used in this analysis were not cal trials used in this analysis were not intended to assess risk factors for diabetes intended to assess risk factors for diabetes or to look for treatment-emergent diabetes, or to look for treatment-emergent diabetes, and caution is warranted when extrapolatand caution is warranted when extrapolating results of this analysis to a more general ing results of this analysis to a more general practice setting. Nevertheless, the clinical practice setting. Nevertheless, the clinical trials were randomised and masked, and trials were randomised and masked, and unlike a number of the retrospective cohort unlike a number of the retrospective cohort s 9 9 s 9 9 studies noted above, more detailed baseline studies noted above, more detailed baseline risk factor information was available for risk factor information was available for study participants. Retrospective analyses study participants. Retrospective analyses cannot definitively answer all questions cannot definitively answer all questions regarding a potential link between schizoregarding a potential link between schizophrenia and diabetes, nor can this type of phrenia and diabetes, nor can this type of analysis resolve whether there are subtle analysis resolve whether there are subtle differences in risk for diabetes among users differences in risk for diabetes among users of different antipsychotic medications. We of different antipsychotic medications. We hope, however, that the results of this hope, however, that the results of this analysis may provide important preanalysis may provide important preliminary information regarding antiliminary information regarding antipsychotic therapy and the relative impact psychotic therapy and the relative impact of pre-existing risk factors for diabetes, of pre-existing risk factors for diabetes, short-term weight gain and use of olanzashort-term weight gain and use of olanzapine on the short-term risk of marked pine on the short-term risk of marked glycaemic abnormalities or diabetes. glycaemic abnormalities or diabetes.
In summary, results of this retrospective In summary, results of this retrospective analysis suggest that over the short term analysis suggest that over the short term (generally less than 1 year's exposure, with (generally less than 1 year's exposure, with a median exposure time of less than 6 a median exposure time of less than 6 months), elevated baseline non-fasting months), elevated baseline non-fasting glucose level and presence of multiple risk glucose level and presence of multiple risk factors for diabetes appear to have a major factors for diabetes appear to have a major impact on the risk of being identified with impact on the risk of being identified with TED, whereas the impact of treatment-TED, whereas the impact of treatmentemergent weight gain on short-term TED emergent weight gain on short-term TED risk was relatively small and was not statisrisk was relatively small and was not statistically significant. Patients treated with tically significant. Patients treated with olanzapine did not have a significantly olanzapine did not have a significantly greater risk of short-term TED compared greater risk of short-term TED compared with a pooled cohort of patients receiving with a pooled cohort of patients receiving risperidone, haloperidol and placebo. Overrisperidone, haloperidol and placebo. Overall, the risk factors for diabetes in patients all, the risk factors for diabetes in patients with schizophrenia overlap those in the with schizophrenia overlap those in the general population. general population. and Cindy Coe Taylor for assistance with preparation of the manuscript. Dr Buse has received honortion of the manuscript. Dr Buse has received honoraria, consulting fees and research grants from Eli aria, consulting fees and research grants from Eli Lilly, Pfizer and Novartis. Since October 2001, by Lilly, Pfizer and Novartis. Since October 2001, by institutional policy aimed at minimising potential duainstitutional policy aimed at minimising potential dualities of interest in the conduct of clinical trials, these lities of interest in the conduct of clinical trials, these funds are received under contract with the Univerfunds are received under contract with the University of North Carolina School of Medicine and are sity of North Carolina School of Medicine and are not of direct financial benefit to Dr Buse. In 2002, not of direct financial benefit to Dr Buse. In 2002, abstracts of this study were presented at abstracts of this study were presented at the American Diabetes Association, the Collegium the American Diabetes Association, the Collegium International Neuro-Psychopharmacologicum, and International Neuro-Psychopharmacologicum, and the Institute on Psychiatric Services annual meetings. the Institute on Psychiatric Services annual meetings. During further investigation of the data set post-publication, an error was observed in the treatment-emergent diabetes (TED) manuscript that led to a thorough data review. Additional errors were discovered. Despite these errors, conclusions from a reanalysis about the impact of pre-existing risk factors on TED are largely unchanged; however, the interpretation of the impact of weight gain on TED has been refined. Four errors had the most impact on the TED analyses.
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First, for calculation of the categorical weight gain risk factor, three programming syntax errors were found. The syntax incorrectly used a >7% criterion as opposed to the appropriate ≥7% criterion for categorical weight gain, it incorrectly grouped patients with weight loss together with patients with weight gain as risk present, and it incorrectly set the value of the weight gain risk variable backwards (ie, if weight gain >7% then weight gain risk = 0 should have been = 1).
Second, for calculation of the overweight risk factor (body mass index [BMI] ≥27 kg/m 2 ), the programming syntax assigned patients to the risk-absent condition if their BMI was incalculable due to missing height data. Therefore, some patients who were overweight were categorized as risk absent. This error also affected the assessment of total number of risk factors, since being overweight was one of the included factors.
Third, a placebo-like 1-mg dose group was used in the analyses when only patients with standard olanzapine dosing (5-20 mg/day) were to be included.
Fourth, when serial glucose values were examined to identify confirmatory results for identification of TED cases, laboratory data were processed based upon highest glucose value across time between visits (from 1 to 8 weeks of time) rather than using each individual actual sample, resulting in a less sensitive process for identification of TED cases.
These errors were corrected in a reanalysis of the data following the approach described in the TED Manuscript. Patients without height data were excluded for analyses that included BMI.
The main findings in the original TED manuscript were incidence of TED and risk factor impact on the risk of developing TED (hazard ratios [HR]). These TED incidence and risk factor results for the "original analysis" and "reanalysis" are summarized below (Table 1 includes full summary of incidence rates). The original analysis included 5,013 patients. The reanalysis included 4,820 patients, largely due to exclusion of the 1-mg dose group (error 3, above). The crude TED incidence for olanzapine-versus placebo-treated patients in the original analysis (2.3% vs. 1.4%, p=0.626) was similar to the incidence of TED in the reanalysis (2.3% vs. 1.0%, p=0.321).
The incidence of TED after adjusting for exposure was not statistically significantly different for olanzapine-treated patients compared to haloperidol-, risperidone-, or placebo-treated patients when these treatment groups were combined or when treated as separate treatment groups in either the original analysis or reanalysis. Patients treated with olanzapine had a statistically significantly lower rate of TED (after adjusting for exposure time) than clozapine-treated patients in both the original analysis (HR not reported in the original analysis, HR = 1.467, p=0.022) and in the reanalysis (HR = 1.387, p=0.018).
As reported in the original analysis, patients with baseline non-fasting glucose ≥6.7 mmol/L were at a greater risk of TED (HR = 11.85, p<0.001) than normoglycaemic patients. The reanalysis provided a similar result (HR = 12.70, p<0.0001). In patients with ≥2 baseline risk factors, the likelihood of TED was also similar between the original analysis (HR = 5.70, p<0.001) and reanalysis (HR = 7.35, p<0.0001). The risk of TED for olanzapine-vs. nonolanzapine-treated (risperidone, haloperidol, and placebo) patients was similar between the original analysis (HR = 1.46, p=0.186) and reanalysis (HR = 1.49, p=0.228), with the risk of TED for olanzapine-treated patients not statistically significantly greater than that of the nonolanzapine-treated patients.
As part of the original analyses, a multivariate analysis was performed, where the continuous variables baseline glucose, number of baseline risk factors, and weight change were included as covariates. As with the univariate analysis, the risk of TED was not statistically different between olanzapine-and non-olanzapine-treated patients (p=0.220). This finding was similar for the reanalysis (p=0.3956).
There was one analysis where the original results where not consistent with those of the reanalysis: impact of ≥7% weight gain on risk of TED. In the original analysis, ≥7% weight gain from baseline was a non-statistically significant risk factor (HR = 1.21, p=0.414). In contrast, in the reanalysis, a statistically significant temporal association was observed between >7% weight gain and a decreased risk of developing diabetes (HR = 0.538, p=0.0174). This finding does not intuitively make sense, given that being overweight is a known risk factor for diabetes.
Therefore, to further evaluate the potential contribution of treatment-emergent weight gain to the risk of TED, an alternative analysis was performed in which baseline weight was included as a fixed covariate and post-baseline weight change was utilized as a time-varying covariate. This methodology is considered to be more appropriate than the approach taken in the original analysis, which modeled weight change as a single post-baseline quantity measured up to the patient's last observation. In this alternative analysis, a multivariate model was used that incorporated baseline weight, each of the five key risk factors for TED (age ≥45 years, baseline nonfasting glucose ≥6.7 mmol/L (120 mg/dL), non-Caucasian origin, baseline hypertension, and female gender), treatment group assignment, and time-varying weight change. In this alternative analysis, weight gain was found to be a statistically significant risk factor (HR = 1.05, p=0.0117). Baseline weight, baseline nonfasting glucose ≥6.7 mmol/L, ≥45 years of age, and non-Caucasian origin were also statistically significant risk factors. Hazard ratio estimates for female gender and hypertension at baseline did not achieve statistical significance but the hazard ratio estimates did exceed 1 (estimate is in the direction of a risk). The risk of TED for patients treated with olanzapine was not statistically significantly different from the non-olanzapine treatment cohort (risperidone, haloperidol, and placebo combined) when adjusted for all other factors included in the model (HR = 1.385, p=0.3455).
Overall, results from the reanalysis and alternative analysis are consistent with the main conclusion from the original TED manuscript: "The majority of patients who were identified as TED were likely to have pre-existing, unrecognized glycaemic abnormalities or to have had a greater burden of pre-existing risk factors for diabetes than patients who appeared to maintain normoglycaemia." and in addition, "…elevated baseline non-fasting glucose level and presence of multiple risk factors for diabetes appear to have a major impact on the risk of being identified with TED, whereas the impact of treatment-emergent weight gain on short-term [< 6-month median exposure] TED risk was relatively small." The risk of TED for patients treated with olanzapine was not statistically significantly different from a pooled cohort of patients receiving comparator treatments, including placebo. Similar to the original analysis, the baseline characteristics of patients identified as UGT were intermediate to those of patients identified as TED or NGT. There is only one substantial difference from the original manuscript that should be noted. The manuscript stated that weight gain "did not have a statistically significant effect on the risk of TED." When using a new, more appropriate characterization of weight gain as a time-varying covariate, weight gain was a statistically significant risk factor of TED. 
